Wavelength-dependent effect of tetra(m-hydroxyphenyl)chlorin for photodynamic therapy in an 'early' squamous cell carcinoma model.
The purpose of the present study was to correlate the wavelength of the irradiation source with the phototoxic activity of tetra(m-hydroxyphenyl)chlorin (mTHPC) in healthy and neoplastic mucosae. The hamster tumour model for early squamous cell carcinoma was used in these experiments. In vitro and in vivo studies have shown that mTHPC absorbs significantly at 652 nm (1, 2). This wavelength is used currently in clinical mTHPC photodynamic therapy (PDT) trials. In order to study the wavelength dependence of the phototoxic effect on normal and tumour tissues, irradiation tests were performed 4 days after injection of 0.5mg kg(-1) mTHPC. An argon-ion pumped dye laser was used as the light source. The light dose of 12 J cm(-2) was delivered at a light dose rate of 150 mW cm(-2). The wavelength was varied between 642.5 and 665 nm at 2.5-nm increments. The PDT damage was evaluated in serial Haematoxylin and Eosin stained sections using a tissue-damage scale. Light between 647.5 and 652.5 nm induced the highest damage to both the healthy and tumour mucosae. At wavelengths equal to or below 645 nm, and equal to or above 655 nm, tissue damage decreased. Wavelengths below 642 nm and above 660 nm did not induce any visible tissue damage. These results suggest that the in vivo optimal wavelength range for PDT with mTHPC is between 647 and 652 nm. This information is essential for selecting an appropriate light source.
Blant
S A
SA
Department of Otolaryngology, Head and Neck Surgery, CHUV Hospital, BH 10, 1011, Lausanne, Switzerland.
Theumann
J F
JF
Forrer
M
M
Wagnières
G
G
Van Den Bergh
H
H
Monnier
P
P
Semin Surg Oncol. 1995 Sep-Oct;11(5):355-9
7569557
J Clin Laser Med Surg. 1996 Oct;14(5):281-7
9612194
Photochem Photobiol. 1994 Oct;60(4):383-7
7991665
Photochem Photobiol. 1996 Dec;64(6):963-8
8972639
Lasers Surg Med. 1989;9(4):405-21
2761336
J Invest Dermatol. 1995 Nov;105(5):672-7
7594642
Phys Med Biol. 1992 Jun;37(6):1219-30
1626022
Pathol Res Pract. 1989 Jun;184(6):567-76
2476791
Int J Exp Pathol. 1996 Feb;77(1):7-14
8664146
Cancer Detect Prev. 1991;15(4):291-301
1794136
J Laryngol Otol. 1993 Dec;107(12):1140-5
8289004
Chest. 1992 Nov;102(5):1319-22
1424843
Int J Cancer. 1995 Oct 9;63(2):198-204
7591204
Dermatology. 1992;184(3):202-4
1382731
J Photochem Photobiol B. 1994 Aug;24(3):195-9
7646616
Cancer Res. 1990 Jul 15;50(14):4441-5
1694722
Int J Cancer. 1994 Jun 15;57(6):883-8
8206681
J Histochem Cytochem. 1955 May;3(3):170-95
14381606
Appl Opt. 1996 Apr 1;35(10):1756-66
21085299
J Dent Res. 1954 Apr;33(2):253-62
13152263
Anticancer Drugs. 1992 Apr;3(2):139-42
1525391
J Natl Cancer Inst. 1993 Mar 17;85(6):443-56
8445672